Clinical Trial Update: TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB). [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results assessing bedaquiline (TMC207) for safety, tolerability, and anti-mycobacterial activity in participants with multi-drug resistan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis
• Tuberculosis

Drugs mentioned

• bedaquiline (bedaquiline)

Snippet

Sponsor: Janssen Infectious Diseases BVBA | Conditions: Tuberculosis | Phase 2 | Status: COMPLETED | Results posted: 2013-06-25